471
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer

, &
Pages 2315-2328 | Accepted 21 Jul 2010, Published online: 23 Aug 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sun-Kyeong Park, Hyun Kyung Chun & Chanhyun Park. (2019) Economic evaluations of oral medications for breast cancer treatment in the U.S.: a systematic review with a focus on cost-effectiveness threshold. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 633-643.
Read now

Articles from other publishers (5)

Gaurav Suri, David Chandiwana, Adam Lee & Rohit Mistry. (2019) Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of Health Economics and Outcomes Research, pages 20-31.
Crossref
Gaurav Suri, David Chandiwana, Adam Lee & Rohit Mistry. (2019) Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of Health Economics and Outcomes Research 6:2, pages 20-31.
Crossref
Virginie Nerich, Sopany Saing, Eva Maria Gamper, Georg Kemmler, Franck Daval, Xavier Pivot & Bernhard Holzner. (2016) Cost–utility analyses of drug therapies in breast cancer: a systematic review. Breast Cancer Research and Treatment 159:3, pages 407-424.
Crossref
Pieter T. de Boer, Geert W. J. Frederix, Talitha L. Feenstra & Pepijn Vemer. (2016) Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer. PharmacoEconomics 34:9, pages 833-845.
Crossref
Vivianne Shih, Alexandre Chan, Feng Xie & Yu Ko. (2012) Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. Value in Health Regional Issues 1:1, pages 46-53.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.